What question did this study set out to answer?

Assess safety and effectiveness of letermovir for CMV prophylaxis in lung transplant recipients.

January 14, 2026Open Forum Infectious DiseasesOpen Access

P-2190. Letermovir use for CMV prophylaxis in lung transplant recipients : A single center experience

View Full Paper

Ask AI

Bookmark

Assess safety and effectiveness of letermovir for CMV prophylaxis in lung transplant recipients.
Single-center, retrospective study at Stanford Health Care.
Evaluated letermovir for primary and secondary CMV prophylaxis from January 2017 to December 2024.
Data included CMV serostatus, initiation/timing of LET, CMV viral load, and clinical outcomes.
Included 43 lung transplant recipients on letermovir prophylaxis.
CMV reactivation occurred in 2.3% of recipients; none attributed to CMV infection.
Mortality rate was 20.9% during treatment, but not due to CMV infection.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective analysis shows lettermovir reduces CMV reactivation in lung transplant recipients, highlighting its potential as an alternative to valganciclovir.

Cite This Study

TORRES et al. (2026) studied this question.

synapsesocial.com/papers/6966e71813bf7a6f02bff62d https://doi.org/10.1093/ofid/ofaf695.2353

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows lettermovir reduces CMV reactivation in lung transplant recipients, highlighting its potential as an alternative to valganciclovir.

P-2190. Letermovir use for CMV prophylaxis in lung transplant recipients : A single center experience

Key Points

Discussion

Implication

Cite This Study

P-2190. Letermovir use for CMV prophylaxis in lung transplant recipients : A single center experience

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider